## Jill P Buyon

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4240450/publications.pdf

Version: 2024-02-01

210 papers

20,735 citations

9234 74 h-index 138 g-index

221 all docs

221 docs citations

times ranked

221

13348 citing authors

#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. New England Journal of Medicine, 2005, 353, 2550-2558.	13.9	962
3	Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry. Journal of the American College of Cardiology, 1998, 31, 1658-1666.	1.2	700
4	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. Annals of Internal Medicine, 2005, 142, 953.	2.0	539
5	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	7.0	501
6	Predictors of Pregnancy Outcomes in Patients With Lupus. Annals of Internal Medicine, 2015, 163, 153-163.	2.0	393
7	Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal Lupus. Circulation, 2012, 126, 76-82.	1.6	363
8	Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. Journal of the American College of Cardiology, 2001, 37, 238-242.	1.2	360
9	Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell, 2016, 166, 88-101.	13.5	340
10	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis and Rheumatology, 2020, 72, 529-556.	2.9	332
11	Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupus. Arthritis and Rheumatism, 1999, 42, 2335-2345.	6.7	291
12	Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block. Circulation, 2008, 117, 485-493.	1.6	282
13	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology, 2019, 20, 915-927.	7.0	275
14	Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Annals of the Rheumatic Diseases, 2019, 78, 947-956.	0.5	274
15	Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus. Circulation, 2011, 124, 1927-1935.	1.6	257
16	Cutaneous manifestations of neonatal lupus without heart block: Characteristics of mothers and children enrolled in a national registry. Journal of Pediatrics, 2000, 137, 674-680.	0.9	231
17	Classification and definition of major flares in SLE clinical trials. Lupus, 1999, 8, 685-691.	0.8	220
18	Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, openâ€label clinical trial. Arthritis and Rheumatism, 2010, 62, 1138-1146.	6.7	211

#	Article	IF	CITATIONS
19	The clinical spectrum of autoimmune congenital heart block. Nature Reviews Rheumatology, 2015, 11, 301-312.	3.5	209
20	Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti–ss-a/ro and anti–ss-b/la antibodies. Arthritis and Rheumatism, 1993, 36, 1263-1273.	6.7	208
21	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Annals of the Rheumatic Diseases, 2010, 69, 1827-1830.	0.5	192
22	High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. Arthritis and Rheumatism, 2001, 44, 1466-1467.	6.7	187
23	Anti-SSA/Ro and Anti-SSB/La Autoantibodies Bind the Surface of Apoptotic Fetal Cardiocytes and Promote Secretion of TNF-α by Macrophages. Journal of Immunology, 2000, 165, 5345-5351.	0.4	181
24	Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatism, 1994, 37, 376-383.	6.7	171
25	Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. American Journal of Cardiology, 2009, 103, 1102-1106.	0.7	171
26	PD-1hiCXCR5– T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight, 2019, 4, .	2.3	171
27	Assessing disease activity in SLE patients during pregnancy. Lupus, 1999, 8, 677-684.	0.8	166
28	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight, 2017, $2$ , .	2.3	164
29	Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis and Rheumatism, 2000, 43, 550.	6.7	162
30	Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Arthritis and Rheumatism, 1987, 30, 44-49.	6.7	154
31	Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis and Rheumatism, 2002, 46, 2377-2383.	6.7	149
32	Pulsed Doppler echocardiographic assessment of the fetal PR interval. American Journal of Cardiology, 2000, 86, 236-239.	0.7	148
33	Arrhythmogenicity of IgG and Anti-52-kD SSA/Ro Affinity-Purified Antibodies From Mothers of Children With Congenital Heart Block. Circulation Research, 1997, 80, 354-362.	2.0	144
34	Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. Journal of Clinical Investigation, 2006, 116, 2413-22.	3.9	140
35	Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis and Rheumatism, 2004, 50, 173-182.	6.7	135
36	Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis and Rheumatism, 2009, 60, 3091-3097.	6.7	135

#	Article	IF	CITATIONS
37	Successful in utero therapy of fetal heart block. American Journal of Obstetrics and Gynecology, 1995, 173, 1384-1390.	0.7	133
38	Hepatobiliary Disease in Neonatal Lupus: Prevalence and Clinical Characteristics in Cases Enrolled in a National Registry. Pediatrics, 2002, 109, e11-e11.	1.0	132
39	The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2006, 54, 3623-3632.	6.7	130
40	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis and Rheumatology, 2017, 69, 2006-2017.	2.9	126
41	Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Annals of the Rheumatic Diseases, 2018, 77, 549-555.	0.5	124
42	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 2016, 214, 108.e1-108.e14.	0.7	122
43	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care and Research, 2020, 72, 461-488.	1.5	122
44	The effects of pregnancy on autoimmune diseases. Journal of Leukocyte Biology, 1998, 63, 281-287.	1.5	120
45	Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis and Rheumatism, 2010, 62, 1153-1157.	6.7	119
46	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Science and Medicine, 2016, 3, e000131.	1.1	118
47	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	1.3	118
48	Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis and Rheumatism, 1988, 31, 632-641.	6.7	115
49	Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. Arthritis and Rheumatism, 2001, 44, 1203-1208.	6.7	111
50	Female hormones reduce neutrophil responsiveness in vitro. Arthritis and Rheumatism, 1984, 27, 623-630.	6.7	108
51	Congenital complete heart block. Arthritis and Rheumatism, 1990, 33, 609-614.	6.7	108
52	Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis and Rheumatism, 1992, 35, 1028-1037.	6.7	104
53	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS &lt; /scp&gt;– <scp>CoV &lt; /scp&gt;â€2 Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.</scp></scp>	2.9	103
54	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 2020, 76, 292-302.	1.2	97

#	Article	IF	CITATIONS
55	Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology, 2012, 51, 1086-1092.	0.9	96
56	Transdifferentiation of Cardiac Fibroblasts, a Fetal Factor in Anti-SSA/Ro-SSB/La Antibody-Mediated Congenital Heart Block. Journal of Immunology, 2002, 169, 2156-2163.	0.4	94
57	Cytokine Polymorphisms and Histologic Expression in Autopsy Studies: Contribution of TNF- $\hat{l}\pm$ and TGF- $\hat{l}^21$ to the Pathogenesis of Autoimmune-Associated Congenital Heart Block. Journal of Immunology, 2003, 171, 3253-3261.	0.4	92
58	Activation of the Alternative Complement Pathway Accompanies Disease Flares in Systemic Lupus Erythematosus During Pregnancy. Arthritis and Rheumatism, 1992, 35, 55-61.	6.7	90
59	Prevention and Treatment In Utero of Autoimmune-Associated Congenital Heart Block. Cardiology in Review, 2014, 22, 263-267.	0.6	90
60	Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. Journal of Rheumatology, 2004, 31, 2480-7.	1.0	90
61	Ro60-Associated Single-Stranded RNA Links Inflammation with Fetal Cardiac Fibrosis via Ligation of TLRs: A Novel Pathway to Autoimmune-Associated Heart Block. Journal of Immunology, 2010, 184, 2148-2155.	0.4	89
62	Serum and Immunoglobulin G from the Mother of a Child with Congenital Heart Block Induce Conduction Abnormalities and Inhibit L-Type Calcium Channels in a Rat Heart Model. Pediatric Research, 1998, 44, 11-19.	1.1	88
63	Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis and Rheumatism, 1998, 41, 1026-1039.	6.7	86
64	NEONATAL LUPUS SYNDROMES. Rheumatic Disease Clinics of North America, 1997, 23, 31-54.	0.8	85
65	Electrocardiographic Abnormalities in a Murine Model Injected With IgG From Mothers of Children With Congenital Heart Block. Circulation, 1999, 99, 1914-1918.	1.6	84
66	Neonatal Lupus: Basic Research and Clinical Perspectives. Rheumatic Disease Clinics of North America, 2005, 31, 299-313.	0.8	84
67	Neonatal Lupus Syndromes. Rheumatic Disease Clinics of North America, 2007, 33, 267-285.	0.8	84
68	Identification of candidate loci at 6p21 and 21q22 in a genomeâ€wide association study of cardiac manifestations of neonatal lupus. Arthritis and Rheumatism, 2010, 62, 3415-3424.	6.7	84
69	Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis and Rheumatism, 2002, 46, 1572-1579.	6.7	83
70	Sex Differences in Systemic Lupus Erythematosus. Mayo Clinic Proceedings, 2020, 95, 384-394.	1.4	83
71	Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. Journal of Immunological Methods, 1990, 129, 207-210.	0.6	82
72	Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Annals of the Rheumatic Diseases, 2016, 75, 1161-1165.	0.5	81

#	Article	IF	Citations
73	Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Current Rheumatology Reports, 2007, 9, 101-108.	2.1	80
74	Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. Cardiovascular Research, 2020, 116, 1446-1457.	1.8	80
75	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. Journal of Rheumatology, 2015, 42, 2288-2295.	1.0	79
76	Activated Platelets Induce Endothelial Cell Activation via an Interleukin- $\hat{\Pi}^2$ Pathway in Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 707-716.	1.1	77
77	Neonatal lupus syndromes. Current Opinion in Rheumatology, 2003, 15, 535-541.	2.0	76
78	Neonatal Lupus: Review of Proposed Pathogenesis and Clinical Data from the US-based Research Registry for Neonatal Lupus. Autoimmunity, 2003, 36, 41-50.	1.2	74
79	Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nature Reviews Rheumatology, 2009, 5, 139-148.	3.5	73
80	The Fetal Doppler Mechanical PR Interval: A Validation Study. Fetal Diagnosis and Therapy, 2004, 19, 31-34.	0.6	71
81	Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. Seminars in Arthritis and Rheumatism, 2003, 33, 140-154.	1.6	70
82	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
83	The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. Arthritis and Rheumatism, 1997, 40, 936-944.	6.7	69
84	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system. Arthritis and Rheumatism, 2002, 46, 202-208.	6.7	69
85	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science and Medicine, 2014, 1, e000056.	1.1	65
86	Letter to the Editor. Lupus, 2003, 12, 646-647.	0.8	64
87	Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis and Rheumatism, 2005, 52, 3079-3086.	6.7	64
88	Cardiac Manifestations of Neonatal Lupus. Cardiology in Review, 2012, 20, 72-76.	0.6	61
89	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. Journal of Experimental Medicine, 2021, 218, .	4.2	61
90	Blockade of Interferonâ€Ĵ³ Normalizes Interferonâ€Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2713-2722.	2.9	60

#	Article	IF	CITATIONS
91	Congenital heart block: Identification of autoantibody binding site on the extracellular loop (domain) Tj ETQq1 1	0.784314	rgBT /Overlo
92	Integrated urine proteomics and renal single-cell genomics identify an IFN- $\hat{l}^3$ response gradient in lupus nephritis. JCI Insight, 2020, 5, .	2.3	57
93	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. Journal of Experimental Medicine, 2019, 216, 1154-1169.	4.2	56
94	A Novel Role of Endothelin-1 in Linking Toll-like Receptor 7-mediated Inflammation to Fibrosis in Congenital Heart Block. Journal of Biological Chemistry, 2011, 286, 30444-30454.	1.6	55
95	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nature Communications, 2020, 11, 2197.	5.8	55
96	Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy. American Journal of Reproductive Immunology, 1992, 28, 183-187.	1.2	53
97	Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 89-95.	1.0	51
98	Leveraging the United States Epicenter to Provide Insights on COVIDâ€19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	2.9	51
99	Complement Receptor 3 Influences Toll-like Receptor 7/8-Dependent Inflammation. Journal of Biological Chemistry, 2013, 288, 9077-9083.	1.6	48
100	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2018, 103, 1074-1082.	2.3	48
101	Ro60 Requires Y3 RNA for Cell Surface Exposure and Inflammation Associated with Cardiac Manifestations of Neonatal Lupus. Journal of Immunology, 2013, 191, 110-116.	0.4	47
102	The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. Rheumatology, 2018, 57, v9-v17.	0.9	47
103	Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor ?: Implications for pathogenesis. Arthritis and Rheumatism, 2004, 50, 2598-2603.	6.7	46
104	Neonatal lupus. Current Opinion in Rheumatology, 2012, 24, 466-472.	2.0	44
105	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 230-235.	1.5	41
106	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1742-1749.	0.5	40
107	Umbilical cord blood levels of maternal antibodies reactive with p200 and fullâ€length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care and Research, 2012, 64, 1373-1381.	1.5	39
108	Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Current Opinion in Rheumatology, 2017, 29, 467-472.	2.0	39

#	Article	IF	CITATIONS
109	Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block. Journal of Immunology, 2019, 202, 48-55.	0.4	39
110	The Incidence and Prevalence of Adult Primary Sj $\tilde{A}$ $\P$ gren's Syndrome in New York County. Arthritis Care and Research, 2019, 71, 949-960.	1.5	38
111	Autoimmune-mediated congenital heart block. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 41-51.	1.4	38
112	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	2.9	38
113	The Effects of Pregnancy on Autoimmune Diseases. Clinical Immunology and Immunopathology, 1996, 78, 99-104.	2.1	37
114	Autoantibody-associated congenital heart block: $TGF\hat{l}^2$ and the road to scar. Autoimmunity Reviews, 2005, 4, 1-7.	2.5	37
115	Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Research and Therapy, 2020, 22, 52.	1.6	37
116	Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clinical Immunology, 2014, 153, 1-7.	1.4	36
117	Clearance of apoptotic cells: $TGF-\hat{l}^2$ in the balance between inflammation and fibrosis. Journal of Leukocyte Biology, 2003, 74, 959-960.	1.5	35
118	Endosomal Tollâ€like receptors inÂclinically overt and silent autoimmunity. Immunological Reviews, 2016, 269, 76-84.	2.8	35
119	Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. Arthritis and Rheumatology, 2018, 70, 1801-1806.	2.9	34
120	Congenital heart block in neonatal lupus: The pediatric cardiologist's perspective. Indian Journal of Pediatrics, 2002, 69, 517-522.	0.3	33
121	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis and Rheumatology, 2016, 68, 1964-1969.	2.9	33
122	Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: A reassessment. Journal of Autoimmunity, 2005, 25, 72-76.	3.0	32
123	Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus. Journal of the American College of Cardiology, 2015, 66, 930-939.	1.2	32
124	Cloning and expression of mouse 60 kDa ribonucleoprotein SS-A/Ro. Molecular Biology Reports, 1996, 23, 205-210.	1.0	31
125	Thoughts on COVID-19 and autoimmune diseases. Lupus Science and Medicine, 2020, 7, e000396.	1.1	31
126	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31

#	Article	IF	CITATIONS
127	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmuneâ€associated congenital heart block. Arthritis and Rheumatism, 2011, 63, 2783-2789.	6.7	30
128	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp> : Assessment by Drug Levels and Selfâ€Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	2.3	30
129	Cardiac 5-HT4 Serotoninergic Receptors, 52kD SSA/Ro and Autoimmune-Associated Congenital Heart Block. Journal of Autoimmunity, 2002, 19, 79-86.	3.0	29
130	Review: Congenital Complete Heart Block. Lupus, 1993, 2, 291-295.	0.8	28
131	Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. Mayo Clinic Proceedings, 2019, 94, 1436-1443.	1.4	28
132	The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: Implications in neonatal lupus. Arthritis and Rheumatism, 2002, 46, 269-271.	6.7	26
133	Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmunity Reviews, 2017, 16, 980-983.	2.5	25
134	Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology, 2008, 48, 513-519.	0.9	24
135	SLE: reconciling heterogeneity. Lupus Science and Medicine, 2019, 6, e000280.	1.1	23
136	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	1.1	22
137	A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. Prenatal Diagnosis, 2020, 40, 1066-1076.	1.1	22
138	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Research and Therapy, 2020, 22, 191.	1.6	21
139	Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS ONE, 2017, 12, e0182483.	1.1	21
140	Serum activity that confers acid lability to $\hat{l}\pm$ -interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating $\hat{l}\pm$ -interferon. Arthritis and Rheumatism, 1990, 33, 563-568.	6.7	20
141	Differential phosphorylation of the $\hat{l}^22$ integrin CD11b/CD18 in the plasma and specific granule membranes of neutrophils. Journal of Leukocyte Biology, 1997, 61, 313-321.	1.5	20
142	Connective tissue disease registries. Arthritis and Rheumatism, 1997, 40, 1556-1559.	6.7	20
143	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. Arthritis Research and Therapy, 2018, 20, 36.	1.6	20
144	Human lowâ€affinity IgG receptor Fcî³RIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus. Journal of Thrombosis and Haemostasis, 2019, 17, 532-537.	1.9	20

#	Article	IF	Citations
145	Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. Journal of Autoimmunity, 2016, 67, 36-45.	3.0	19
146	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine, 2016, 3, e000165.	1.1	18
147	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine, 2018, 5, e000263.	1.1	18
148	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatology, The, 2021, 3, e585-e594.	2.2	18
149	mRNA and Protein Expression of SSA/Ro and SSB/La in Human Fetal Cardiac Myocytes Cultured Using a Novel Application of the Langendorff Procedure. Pediatric Research, 1999, 45, 260-269.	1.1	18
150	Heterogeneity in the expression of ro and la antigens in human skin. Arthritis and Rheumatism, 1995, 38, 1271-1276.	6.7	17
151	A 2014 update on the management of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 44, e1-e2.	1.6	17
152	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
153	From antibody insult to fibrosis in neonatal lupus - the heart of the matter. Arthritis Research, 2003, 5, 266.	2.0	16
154	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	2.1	16
155	Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H631-H640.	1.5	15
156	Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Science Alliance, 2021, 4, e202101180.	1.3	15
157	Updates on lupus and pregnancy. Bulletin of the NYU Hospital for Joint Diseases, 2009, 67, 271-5.	0.7	14
158	Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. Journal of Autoimmunity, 2017, 79, 99-104.	3.0	13
159	A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Science and Medicine, 2015, 2, e000087.	1.1	12
160	Onset and Regulation of Anti-Lamin b Autoantibody Production is Independent of the Level of Polyclonal Activation. Autoimmunity, 1991, 8, 297-305.	1.2	11
161	Neonatal Lupus. , 2011, , 541-571.		11
162	A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. Rheumatology, 2013, 52, 1448-1453.	0.9	11

#	Article	IF	CITATIONS
163	Brief Report: Association of Natural Killer Cell Ligand Polymorphism HLA-C Asn80Lys With the Development of Anti-SSA/Ro-Associated Congenital Heart Block. Arthritis and Rheumatology, 2017, 69, 2170-2174.	2.9	11
164	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. Journal of Rheumatology, 2022, 49, 388-397.	1.0	11
165	Identifying an early marker for congenital heart block: When is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis and Rheumatism, 2005, 52, 1341-1342.	6.7	10
166	Modulation of natural IgM autoantibodies to oxidative stress-related neo-epitopes on apoptotic cells in newborns of mothers with anti-Ro autoimmunity. Journal of Autoimmunity, 2016, 73, 30-41.	3.0	10
167	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000475.	1.1	10
168	Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. Experimental and Molecular Pathology, 2013, 95, 121-123.	0.9	9
169	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
170	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatology, The, 2022, 4, e582-e585.	2.2	9
171	Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. Journal of Thrombosis and Thrombolysis, 2018, 45, 13-17.	1.0	8
172	Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. Lupus Science and Medicine, 2018, 5, e000271.	1.1	8
173	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials.―by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45. Autoimmunity Reviews, 2014, 13, 70-72.	2.5	7
174	Reactivity to the p305 Epitope of the α <sub>1G</sub> Tâ€Type Calcium Channel and Autoimmuneâ€Associated Congenital Heart Block. Journal of the American Heart Association, 2015, 4, .	1.6	7
175	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	1.1	7
176	Estrogens and lupus: Bubbling cauldron or another overrated Witches' Brew?. Arthritis and Rheumatism, 2007, 56, 1048-1050.	6.7	6
177	Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis. Journal of Rheumatology, 2012, 39, 510-515.	1.0	6
178	Single-cell RNA sequencing for the study of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000329.	1.1	6
179	Factors associated with long-term cardiac dysfunction in neonatal lupus. Annals of the Rheumatic Diseases, 2020, 79, 217-224.	0.5	6
180	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	0.9	6

#	Article	IF	Citations
181	Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. Gut Microbes, 2022, 14, .	4.3	6
182	Autoantibody-associated congenital heart block: The clinical perspective. Current Rheumatology Reports, 2003, 5, 374-378.	2.1	5
183	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	1.1	5
184	No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clinical and Experimental Rheumatology, 2017, 35, 857-859.	0.4	4
185	Reducing the burden of surveillance in pregnant womenÂwith no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers. American Journal of Obstetrics and Gynecology, 2022, 227, 761.e1-761.e10.	0.7	4
186	Neonatal Lupus. , 2014, , 251-272.		3
187	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
188	Clinical trials in systemic lupus erythematosus. Current Rheumatology Reports, 2000, 2, 11-12.	2.1	2
189	Neonatal Lupus Erythematosus. , 2016, , 336-350.e8.		2
190	Microvascular endothelial glycocalyx thickness is associated with brachial artery flow-mediated dilation. Vascular Medicine, 2021, 26, 563-565.	0.8	2
191	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system., 2002, 46, 202.		2
192	1206â€Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
193	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. Arthritis Care and Research, 0, , .	1.5	2
194	Neonatal Lupus Syndromes: Clinical Features. Handbook of Systemic Autoimmune Diseases, 2003, , 163-188.	0.1	1
195	Neonatal Lupus. , 2016, , 451-461.		1
196	Neonatal Lupus. , 2019, , 486-498.		1
197	Gerald Weissmann: Inflammation in rheumatic disease. Annals of the Rheumatic Diseases, 2020, 79, 435-436.	0.5	1
198	Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment. , $2021$ , , $507-519$ .		1

#	Article	IF	Citations
199	To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Antiâ€SSA/Ro. Journal of the American Heart Association, 0, , .	1.6	1
200	Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue. Lupus Science and Medicine, 2014, 1, e000033.	1.1	0
201	GC-02â€Apolipoprotein L1 risk variants associate with increased SLE damage independent of inflammation in ghanaian SLE patients. , 2018, , .		0
202	Al-06â€Lupus nephritis is linked to dysbiosis, increased gut leakiness and immunity to an intestinal commensal lachnospiracaea species. , 2018, , .		0
203	273â€Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. , 2019, , .		0
204	300â€Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. , 2019, , .		0
205	Breast feeding in the systemic lupus erythematosus patient. Lupus, 2020, 29, 1314-1315.	0.8	0
206	598: The effect of maternal autoimmune disease on fetal thymus size in the mid-trimester. American Journal of Obstetrics and Gynecology, 2020, 222, S384.	0.7	0
207	Passively acquired lupus in the fetus and neonate. , 2021, , 325-363.		0
208	511â€Disease flares in lupus are concordant with ⟨i⟩Ruminococcus Blautia Gnavus⟨/i⟩ blooms arising within unstable gut microbiota communities. , 2021, , .		0
209	901â€Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. , 2021, , .		0
210	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0